Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens

Annals of Oncology

Volumn 11, Issue SUPPL. 1, 2000, Pages

  Treon, S P ^a,c   Shima, Y ^a   Grossbard, M L ^a   Preffer, F I ^a   Belch, A R ^b   Pilarski, L M ^b   Anderson, K C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

B cells; CD20; Core protein; Dexamethasone; Immunotherapy; Interferon gamma; Muc 1; Multiple myeloma; Plasma cells; Rituximab

Indexed keywords

CD20 ANTIGEN; DEXAMETHASONE; GAMMA INTERFERON; RITUXIMAB;

ANTIBODY DEPENDENT LYMPHOCYTOTOXICITY; ANTIGEN EXPRESSION; B LYMPHOCYTE; CONFERENCE PAPER; IMMUNOTHERAPY; MULTIPLE MYELOMA; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; WALDENSTROEM MACROGLOBULINEMIA;

EID: 0033996882     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/11.suppl_1.S107     Document Type: Conference Paper

References (53)

1. American Cancer Society. CA-Facts for the Clinician 1997.
2. Dimopoulos MA, Alexanian R. Waldenstrom's macroglobulinemia. Blood 1994; 83: 1452.
3. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825.
4. 131I-B1 (anti-CD20) antibody therapy with autologous stem-cell transplantation for relapsed B-cell lymphomas. Lancet 1995; 346: 336.
5. Kaminski MS, Zasadny KR, Francis IR et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996; 14: 1974.
6. Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268.
7. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998; 92: 1927.
8. Witzig T, White CA, Wiseman G et al. IDEC-Y2B8 radioimmunotherapy: Responses in patients with splenomegaly. Blood 1998; 92: 417a.
9. Goldmacher VS, Bourret LA, Levine BA et al. Anti-CD38-blocked ricin: An immunotoxin for the treatment of multiple myeloma. Blood 1994; 84: 3017.
10. Grossbard ML, Fidia P, Kinsella J et al. Anti-B4-blocked ricin: A phase II trial of seven-day continuous infusion in patients with multiple myeloma. Br J Haematol 1998; 102: 509.
11. Treon SP, Mollick JA, Urashima M et al. Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood 1999; 93: 1287.
12. Treon SP, Shima Y, Preffer I et al. Treatment of plasma cell dyscrasias by antibody mediated immunotherapy. Semin Oncol 1999 (in press).
13. Szczepek AJ, Seeberger K, Wizniak J et al. A high frequency of circulating B cells share clonotypic IgH VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ RT-PCR. Blood 1998; 92: 2844.
14. Bergsagel PL, Masellis Smith A, Szczepek A et al. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic immunoglobulin light chain. Blood 1995; 85: 436.
15. Bergsagel PL, Belch AR, Pilarksi LM. The blood B cells and bone marrow plasma cells in a patient with multiple myeloma include cells with the same N-ras mutation. Blood 1994; 84: 524a.
16. Treon SP, Shima Y. Preffer FI et al. Interferon-γ induces CD20 expression on multiple myeloma patient and healthy donor plasma cells and B cells and augments binding of Rituximab (Rituxan). Proceedings of the International Conference on Malignant Lymphoma. Ann Oncol 1999; 10 (Suppl 3): 34 (Abstr).
17. Patton S, Gendler SJ, Spicer AP. The epithelial mucin, Mucl, of milk, mammary gland and other tissues. Biochim Biophys Acta 1995; 1241: 407.
18. Burchell J, Pemberton L, Lalani EN, Wilson D. Molecular cloning and expression of human tumor associated polymorphic epithelial mucin. J Biol Chem 1990; 265: 15286.
19. Petrakou E, Murray A, Price MR. Epitope mapping of anti-Mucl mucin protein core monoclonal antibodies. Tumor Biol 1998; 19: 21.
20. Dai J, Allard WJ, Davis G, Yeung KK. Effect of desialylation on binding, affinity, and specificity of 56 monoclonal antibodies against Mucl mucin. Tumor Biol 1998; 19: 100.
21. Tsarfaty I, Hareuveni M, Horev J et al. Isolation and characterization of an expressed hypervariable gene coding for a breast cancer associated antigen. Gene 1990; 93: 313.
22. Lancaster CA, Peat N, Duhig T et al. Structure and expression of the human polymorphic epithelial mucin gene: An expressed VNTR unit. Biochem Biophys Res Commun 1990; 173: 1019.
23. Surveyor GA, Gendler SJ, Pemberton L et al. Expression and steroid hormonal control of Muc-1 in the mouse uterus. Endocrinology 1995; 136: 3639.
24. Hild-Petito S, Fazleabas AT, Julian J, Carson DD. Mucin (Muc-1) expression is differentially regulated in uterine luminal and glandular epithelia of the baboon. Biol Reprod 1996; 54: 939.
25. Byrd JC, White CA, Link B et al. Rituximab therapy in previously treated Waldenstrom's macroglobulinemia: Preliminary evidence of activity. Blood 1998; 92: 106a.
26. Leo R, Boeker M, Peest D et al. Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, c1g+ is the common phenotype of myeloma cells. Ann Hematol 1992; 64: 132.
27. Anderson KC, Bates MP, Slaughenhoupt BL et al. Expression of human B-cell-associated antigens on leukemias and lymphomas: A model of human B-cell differentiation. Blood 1984; 63: 1424.
28. Pilarski LM, Masellis-Smith A, Szczepek A et al. Circulating clonolypic B cells in the biology of multiple meloma: Speculations on the origin of myeloma. Leuk Lymph 1996; 22: 375.
29. Takashita M, Kosaka M, Goto T, Saito S. Cellular origin and extent of clonal involvement in multiple myeloma: Genetic and phenotypic studies. Br J Haematol 1994; 87: 735.
30. Yaccoby S, Barlogie B, Epstein J. Mature myeloma cells are proliferative with self renewal potential. Blood 1997; 92: 588a.
31. Yaccoby S, Johnson CL, Barlogie B, Epstein J. Transfer of myeloma plasma cells but not plasma cell depleted bone marrow and blood cells cause myeloma in healthy hosts. Blood 1998; 92: 261.
32. Himmelmann A, Riva A, Wilson GL et al. Pu.1/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 promoter to help confer lineage- and stage-specific expression of CD20 in B lymphocytes. Blood 1997; 90: 3984.
33. Pettersson M, Sundstrom C, Nilsson K, Larsson LG. The hematopoietic transcription factor PU.1 is downregulated in human multiple myeloma cell lines. Blood 1995; 86: 2747.
34. Karmann K, Hughes CC, Schechner J et al. CD40 on human endothelial cells: Inducibility by cytokines and functional regulation of adhesion molecule expression. PNAS 1995; 92: 4342.
35. Hariharan D, Douglas SD, Lee B et al. Interferon-γ upregulates CCR5 expression in cord and adult blood mononuclear phagocytes. Blood 1999; 93: 1137.
36. Gastl G, Ebert T, Finstad CL et al. Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by inteferon gamma. J Urol 1996; 155: 361.
37. Akbar SM, Inaba K, Onji M. Upregulation of MHC class II antigen on dendritic cells from hepatitis B virus transgenic mice by inteferon-gamma: Abrogation of immune response defect to a T-cell-dependent antigen. Immunology 1996; 87: 519.
38. Schiff DE, Rae J, Martin TR et al. Increased phagocyte Fe gammaR1 expression and improved Fe gamma-receptor-mediated phagocytosis after in vivo recombinant human interferon-gamma treatment of normal human subjects. Blood 1997; 90: 3187.
39. Pandita R, Pocsik E, Aggarwal BB. Interferon-gamma induces cell surface expression for both types of tumor necrosis factor receptors. FEBS Lett 1992; 312: 87.
40. Douillard JY, Mouren M, Fety R et al. Comparative pharmacokinetics of recombinant human gamma interferon after subcutaneous or intrapleural injection in malignant pleural effusion. Proc Annu Meet Am Assoc Cancer Res 1992; 33: A3154.
41. Lane HC, Davey RT, Sherwin SA et al. A phase I trial of recombinant human interferon gamma in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS). J Clin Oncol 1989; 9: 351.
42. Weiner LM, Steplewski Z, Koprowski H et al. Divergent dose-related effects of gamma-interferon therapy on in vitro antibody dependent cellular and nonspecific cytotoxicity by human peripheral monocytes. Cancer Res 1988; 48: 1042.
43. Weiner LM, Moldofsky PJ, Gatenby RA et al. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma. Cancer Res 1988; 48: 2568.
44. Ralph P, Nakoinz I, Rennick D. Role of interleukin-2, interleukin-4, and alpha, beta, and gamma interferon in stimulating macrophage antibody-dependent tumoricidal activity. J Exp Med 1988; 167: 712.
45. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435.
46. Urashima M, Teoh G, Chauhan D et al. Interleukin-6 overcomes p21 WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells. Blood 1997; 90: 279.
47. Einhorn S, Fernberg JO, Grander D, Lewensohn R. Interferon exerts a cytotoxic effect on primary human myeloma cells. Eur J Cancer Clin Oncol 1988; 24: 1505.
48. Portier M, Zhang XG, Caron E et al. Gamma-interferon in multiple myeloma: Inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro. Blood 1993; 81: 3076.
49. Rlasfar A, Wietzerbin J, Billard C. Differential regulation of interleukin-6 receptors by interleukin-6 and interferons in multiple myeloma cell lines. Eur J Immunol 1994; 24: 124.
50. Treon SP, Anderson KC. Interleukin-6 in multiple myeloma and related plasma cell dyscrasias. Curr Opin Hematol 1998; 5: 42.
51. Kobayashi Y, Urabe A. Gamma-interferon therapy of cancer patients. Jpn J Cancer Chemother 1988; 15: 804.
52. Kaminski MS, Vose J, Saleh M et al. A multicenter phase II study of iodine-131 unti-B1 antibody (Bexxar) in patients with chemotherapy relapsed/refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphoma. Blood 1997; 90: 509a.
53. Witzig T, White CA, Wiseman G et al. IDEC-Y2B8 Radioimmunotherapy: Responses in patients with splenomegaly. Blood 1998; 92: 417a.